OncoMatch/Clinical Trials/NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT04634552 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Talquetamab for hematological malignancies.
Treatment: Talquetamab — The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy or T cell redirection therapy
Exception: Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- City of Hope · Duarte, California
- Memorial Healthcare System · Hollywood, Florida
- Emory University Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify